WHO inihinto muna ang trial sa hydroxychloroquine bilang gamot sa COVID-19

By Dona Dominguez-Cargullo May 26, 2020 - 11:36 AM

Sinuspinde pansamantala ng World Health Organization (WHO) ang pagsasagawa ng trial sa hydroxychloroquine bilang pang-gamot sa COVID-19.

Ito ay matapos ang artikulo na lumabas sa medical journal na The Lancet na nagsasabing maari itong magdulot ng mataas na mortality.

Dalawang buwan ang nakararaan nang ilunsad ng WHO at partners ang Solidarity Trial sa gamot para subukan ang pagiging epektibo at ligtas nito.

Mahigit 400 ospital sa 35 bansa ang nag-recruit ng mga pasyente.

Kaya sa ngayon halos 3,500 na pasyente na ang tumugon para lumahok sa trial mula sa 17 mga bansa.

Pero noong Biyernes, isinapubliko ng The Lancet ang observational study nito tungkol sa epekto ng hydroxycholoroquine at chloraquine sa mga pasyente.

Ayon kay WHO Director-General Tedros Adhanom Ghebreyesus nagpulong ang executive group ng Solidarity Trial na kumkatawan sa 10 participating countries at napagkasunduan na rebisahin muna ang mga ebidensya na nakalap sa iba’t ibang mga bansa.

 

 

TAGS: clinical trial, covid pandemic, COVID-19, department of health, general community quarantine, Health, hydroxychloroquine, Inquirer News, Modified enhanced community quarantine, News in the Philippines, Radyo Inquirer, Solidarity Trial, State of Emergency, Tagalog breaking news, tagalog news website, WHO, clinical trial, covid pandemic, COVID-19, department of health, general community quarantine, Health, hydroxychloroquine, Inquirer News, Modified enhanced community quarantine, News in the Philippines, Radyo Inquirer, Solidarity Trial, State of Emergency, Tagalog breaking news, tagalog news website, WHO

Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Cebudailynews. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.